CVS Health (NYSE: CVS) reported Q2 EPS of $2.21, $0.08 better than the analyst estimate of $2.13. Revenue for the quarter came in at $88.92 billion versus the consensus estimate of $86.41 billion.

GUIDANCE:

CVS Health sees FY2023 EPS of $8.50-$8.70, versus the consensus of $8.59.

For earnings history and earnings-related data on CVS Health (CVS) click here.